# A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT07336472** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Fortvita Biologics (USA)Inc.** · enrollment: 360 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** IBI3003

## Key facts

- **NCT ID:** NCT07336472
- **Lead sponsor:** Fortvita Biologics (USA)Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07336472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07336472, "A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07336472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*